Select A LocationTulissin® 100
(tulathromycin injection)
Injectable Solution
Tulissin® 100 injectable solution is a ready-to-use sterile parenteral preparation containing tulathromycin, a semi-synthetic macrolide antibiotic of the subclass triamilide. Each mL of Tulissin® 100 injectable solution contains 100 mg of tulathromycin.
Take a New Breath™
Tulissin® 100 (tulathromycin injection) provides a new standard of performance, flexibility and convenience for managing respiratory disease.
Tulathromycin, a first choice therapy1 for treating Swine Respiratory Disease (SRD):
- Goes to work in minutes2
- Concentrates in the most susceptible areas of the respiratory system
- Provides nine days of lung activity to treat and control SRD2
- Convenient dosages with availability of Tulissin® 25 (tulathromycin injection) for use in smaller pigs with the same pre-slaughter withdraw time of five days
Tulissin® 100 (tulathromycin injection) Tulissin® 25 (tulathromycin injection)
IMPORTANT SAFETY INFORMATION FOR SWINE
Ensure a pre-slaughter withdrawal time of five (5) days in swine. Do not use in animals known to be hypersensitive to the product.
Tulissin® 100 (tulathromycin injection) a first choice therapy for treating bovine respiratory disease (BRD)
- Fast-acting treatment and control of bovine respiratory disease (BRD)
- Goes to work in minutes to treat and control respiratory disease in high-risk cattle1
- Concentrates in the most susceptible areas of the respiratory system5
- Just one shot required for treatment and control with 18-day pre-slaughter withdrawal period
- Patented3 container design features an easy-grip silicone shell that offers excellent shock- absorption properties. This exclusive packaging protects 250 mL and 500 mL vials against breakage, providing 92% resistance4 when dropped multiple times from a height of up to four feet. See the protective shell in action.
IMPORTANT SAFETY INFORMATION FOR CATTLE
Tulissin® 100 (tulathromycin injection): Not for use in humans. Ensure a pre-slaughter withdrawal time of eighteen (18) days in cattle. Do not use in dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. The effects of tulathromycin on bovine reproductive performance, pregnancy and lactation have not been determined. Do not use in animals known to be hypersensitive to the product.
- Villarino N, Brown SA, Martin-Jimenez T. Understanding the pharmacokinetics of tulathromycin: a pulmonary perspective. J Vet Pharmacol. Ther. 2014;37(3):211-221.
- Waag TA, Bradford JR, Lucas MJ, et al. Duration of effectiveness of tulathromycin injectable solution in an Actinobacillus pleuropneumoniae respiratory-disease challenge model in swine. J Swine Health Prod. 2008;16(3):126–130.
- Patent application n°WO2019201812 Registered international design n°DM/103483.
- Internal study.
- Foster DM, Martin LG, Papich MG. Comparison of Active Drug Concentrations in the Pulmonary Epithelial Lining Fluid and Interstitial Fluid of Calves Injected with Enrofloxacin, Florfenicol, Ceftiofur, or Tulathromycin. PLoS ONE. 2016;11(2):e149100.
Beef and Non-Lactating Dairy Cattle
BRD – Tulissin® 100 Injectable Solution is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
IBK – Tulissin® 100 Injectable Solution is indicated for the treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis.
Foot Rot – Tulissin® 100 Injectable Solution is indicated for the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.
Suckling Calves, Dairy Calves, and Veal Calves
BRD – Tulissin® 100 Injectable Solution is indicated for the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis.
DOSAGE AND ADMINISTRATION
Cattle
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site.
Table 1. Tulissin® 100 Cattle Dosing Guide
| Animal Weight (Pounds) | Dose Volume (mL) |
| 100 | 1.1 |
| 200 | 2.3 |
| 300 | 3.4 |
| 400 | 4.5 |
| 500 | 5.7 |
| 600 | 6.8 |
| 700 | 8.0 |
| 800 | 9.1 |
| 900 | 10.2 |
| 1000 | 11.4 |
Swine
Tulissin® 100 Injectable Solution is indicated for the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
DOSAGE AND ADMINISTRATION
Swine
Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (0.25 mL/22 lb) BW. Do not inject more than 2.5 mL per injection site.
Table 2. Tulissin® 100 Swine Dosing Guide
| Animal Weight (Pounds) | Dose Volume (mL) |
| 15 | 0.2 |
| 30 | 0.3 |
| 50 | 0.6 |
| 70 | 0.8 |
| 90 | 1.0 |
| 110 | 1.3 |
| 130 | 1.5 |
| 150 | 1.7 |
| 170 | 1.9 |
| 190 | 2.2 |
| 210 | 2.4 |
| 230 | 2.6 |
| 250 | 2.8 |
| 270 | 3.1 |
| 290 | 3.3 |
RESIDUE WARNINGS
Cattle
Cattle intended for human consumption must not be slaughtered within 18 days from the last treatment. This drug is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows.
Swine
Swine intended for human consumption must not be slaughtered within 5 days from the last treatment.
- Tulissin®100 Injectable Solution is available in the following package sizes:
50 mL vial; 100 mL vial; 250 mL vial; 500 mL vial - New, patented4 container design features an easy-grip silicone shell that offers excellent shock absorption properties. The innovative shell helps dramatically reduce the risk of economic loss, environmental contamination and lack of compliance if treatment is stopped.
- This exclusive packaging protects 250 mL and 500 mL vials against breakage, providing 92% Resistance5 when dropped multiple times from a height of up to four feet.
- 100 mg of tulathromycin/mL
Approved by FDA under ANADA # 200-669.
The labeling contains complete use information, including any cautions and warnings. Always read, understand and follow the labeling and use directions. See the reverse side for use directions and additional information.
